Geron Corporation (GERN) |
|
2.33 0.05 (2.19%)
|
03-24 16:00 |
|
Open: |
2.3 |
Pre. Close: |
2.28 |
|
High:
|
2.345 |
Low:
|
2.24 |
|
Volume:
|
3,547,658 |
Market Cap:
|
1,185(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:26:23 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 3.09 One year: 3.42 |
| Support: |
Support1: 2.2 Support2: 1.83 |
| Resistance: |
Resistance1: 2.65 Resistance2: 2.93 |
| Pivot: |
2.57  |
| Moving Average: |
MA(5): 2.34 MA(20): 2.62
MA(100): 2.6 MA(250): 2.17 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 12.2 %D(3): 9.5 |
| RSI: |
RSI(14): 33.3 |
| 52-week: |
High: 3.83 Low: 1.17 |
| Average Vol(K): |
3-Month: 9,287 (K) 10-Days: 7,171 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GERN ] has closed above bottom band by 17.2%. Bollinger Bands are 21.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.35 - 2.37 |
2.37 - 2.38 |
|
Low:
|
2.2 - 2.22 |
2.22 - 2.24 |
|
Close:
|
2.3 - 2.33 |
2.33 - 2.36 |
|
Company Description |
|
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California. |
Headline News |
Wed, 22 Mar 2023
Geron (GERN) Dips More Than Broader Markets: What You Should ... - Nasdaq
Mon, 20 Mar 2023
Geron Corporation (NASDAQ:GERN) Q4 2022 Earnings Call Transcript - Yahoo Finance
Sat, 18 Mar 2023
Geron (NASDAQ:GERN) Issues Earnings Results - MarketBeat
Fri, 17 Mar 2023
Geron: After Study Results And Q4 Updates, Outlook Still Too ... - Seeking Alpha
Fri, 17 Mar 2023
Geron (NASDAQ:GERN) Now Covered by StockNews.com - MarketBeat
Thu, 16 Mar 2023
Geron (GERN) Q4 2022 Earnings Call Transcript - The Motley Fool
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
509 (M) |
|
% Held by Insiders
|
4.8072e+008 (%) |
|
% Held by Institutions
|
0.1 (%) |
|
Shares Short
|
24,550 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.3826e+008 |
|
EPS Est Next Qtl
|
-0.06 |
|
EPS Est This Year
|
-0.19 |
|
EPS Est Next Year
|
-0.02 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-23 |
|
Return on Assets (ttm)
|
246.6 |
|
Return on Equity (ttm)
|
-41.6 |
|
Qtrly Rev. Growth
|
596000 |
|
Gross Profit (p.s.)
|
-115.52 |
|
Sales Per Share
|
-176.27 |
|
EBITDA (p.s.)
|
-1.2009e+008 |
|
Qtrly Earnings Growth
|
-0.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-127 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-1.4 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.02 |
|
Price to Cash Flow
|
9.08 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
2.46e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
